CClinicalTrials.gg
RecruitingNCT06962644Updated May 8, 2025

Association of Urinary Tract Infection With Preeclampsia During Pregnancy

An observational study in Urinary Tract Infection (Diagnosis) and Preeclampsia, sponsored by Pakistan Air Force (PAF) Hospital Islamabad. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Pakistan Air Force (PAF) Hospital Islamabad · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Urinary tract infections (UTIs) are a major clinical issue, especially in pregnant women, due to physiological changes that increase susceptibility. If untreated, UTIs can lead to severe complications like preterm labor and low birth weight. Preeclampsia, a hypertensive disorder affecting 0.2-9.2% of pregnancies, is another leading cause of maternal and fetal complications. The relationship between UTIs and preeclampsia remains controversial, with some studies suggesting an association while others show conflicting results. Research gaps highlight the need for region-specific studies, particularly in Pakistan, where both conditions contribute significantly to maternal and neonatal morbidity.

This study aims to investigate the association between UTIs and preeclampsia in pregnant women in Pakistan. It will use a cohort design, enrolling 160 patients (80 with UTIs, 80 without) from the Obstetrics Department of PAF Hospital, Islamabad. Participants will be followed until delivery, with preeclampsia diagnosed based on blood pressure and proteinuria criteria. Data will be analyzed using SPSS to calculate relative risk (RR), with statistical significance set at RR >1 and p ≤ 0.05. The findings could help improve prenatal care and reduce adverse outcomes in high-risk populations.

Read the detailed description

INTRODUCTION Urinary tract infections (UTIs) are a significant clinical concern, representing one of the most common bacterial infections in women, particularly during pregnancy. Globally, UTIs account for a substantial proportion of healthcare visits and are implicated in severe complications, including maternal and neonatal morbidity. The physiological and anatomical changes that occur during pregnancy, such as urinary stasis, hormonal influences, and alterations in the immune system, increase susceptibility to both asymptomatic bacteriuria and symptomatic UTIs. These infections can escalate to severe outcomes if untreated, with potential risks to maternal and fetal health, including preterm labor, low birth weight, and perinatal mortality. Concurrently, preeclampsia, a hypertensive disorder of pregnancy, which 0.2 to 9.2% of pregnancies, remains a leading cause of maternal and fetal complications. With its multifactorial etiology involving placental ischemia, systemic inflammation, and endothelial dysfunction, preeclampsia poses a critical challenge in obstetric care.

The relationship between UTIs and preeclampsia is an area of considerable clinical interest yet remains controversial. While some studies have highlighted an association between maternal infections, including UTIs, and an increased risk of preeclampsia, others have yielded conflicting results. Factors such as immune system dysregulation, systemic inflammation, and endothelial dysfunction, which are central to preeclampsia, may be exacerbated by UTIs. Despite extensive research, inconsistencies in prevalence estimates, study designs, and patient populations have hindered a definitive understanding of this association. One study found that 40% and 17.5% patients developed preeclampsia with and without UTI exposure respectively (p value 0.036). The relative risk (RR) was 2.47 (95%CI 1.1789 to 5.1777) with p value of 0.0166. Another study showed that UTI increases the risk of preeclampsia the OR was significant, but RR was not significant. [OR=1.86, (95% Confidence: 2.235-1.608) (p\<0.043), RR 1.2028 (95%CI 0.9018 to 1.6041, p = 0.2089).

The results of a study showed that among 393 pregnant women enrolled, 110 (28.0%), had significant bacteriuria and women with preeclampsia had 7.7 odds of having significant bacteriuria (p-value \<0.001). Radu, V. D., et al. found that there was no association of UTI and preeclampsia (aOR 2.07 with 95% CI 0.63-6.65, P value = 0.22). These knowledge gaps underscore the need for region-specific studies to assess whether UTIs contribute to preeclampsia and how they might influence maternal and perinatal outcomes, particularly in populations with distinct socioeconomic, healthcare, and environmental factors.

This study aims to investigate the association between UTIs and preeclampsia during pregnancy in Pakistan, where both conditions significantly contribute to maternal and neonatal morbidity and mortality. Pakistan's high burden of maternal infections and hypertensive disorders of pregnancy necessitates targeted research to identify preventable risk factors and improve clinical outcomes. 3, 6 By exploring the interplay between UTIs and preeclampsia, this research seeks to provide evidence-based insights that can inform public health strategies, enhance prenatal care protocols, and ultimately reduce the adverse effects of these conditions on maternal and fetal health in this region.

OBJECTIVE To find association of urinary traction infection with preeclampsia in pregnancy.

OPERATIONAL DEFINITIONS Urinary tract infection (UTI): It will be defined as >15 pus cells/high power field (HPF) in clean catch midstream urine after centrifugation and sedimentation.

Preeclampsia: It will be defined as BP >140/90 mmHg on minimum two occasions after 20 weeks of pregnancy alongside presence of proteinuria (≥300 mg/day or at least 1+ dipstick testing or spot urine protein/creatinine ratio of ≥30 mg/mmol).

HYPOTHESIS There is an association of urinary traction infection with preeclampsia in pregnancy.

METHODS AND MATERIALS Study design: Cohort study. Setting: Obstetrics and Gynecology Department, PAF Hospital, Islamabad. Duration of study: The study will be completed in a minimum of six months' time after approval of synopsis.

Sample Size: A sample size of 160 patients (80 exposed, 80 non-exposed) is calculated using 5% level of significance, 80% power of test. The frequency of UTI was taken as 30% in preeclampsia group and 12.1% in non-preeclampsia group.

Sampling technique: Non-probability consecutive sampling Inclusion Criteria

  1. Patients attending OPD for routine antenatal checkup. 2. Patients with UTI as per operational definitions. 3. Patients with gestational age >20 weeks as per LMP 4. Age range of 18 to 35 years Exclusion Criteria
  1. Patients with history of medical conditions like diabetes mellitus, chronic hypertension, chronic liver or kidney diseases, chronic pulmonary conditions.
  2. Patients with history of urological surgical interventions in past 3 months.
  3. Patients with history of renal transplants.
  4. Patients on immunosuppression.
  5. Patients with history of comorbid conditions like diabetes mellites, gestational diabetes mellitus, hypertension, chronic hepatic diseases, chronic liver diseases, chromic pulmonary diseases and ischemic heart diseases.
  6. Patients with history of drugs intake during last one month which can cause proteinuria (NSAIDS, chemotherapeutic drugs, hydralazine, angiotensin receptor blockers).
  7. Patients with a history of coagulation disorders.
  8. Patients who are not willing for consent.

Data Collection Procedure:

After the study approval from the Ethical Review Committee, 160 women (80 exposed, 80 non-exposed) will be selected from the OPD of Obstetrics, PAF Hospital, Islamabad after fulfilling the required selection criteria. All the patients will be counselled regarding the research protocol and informed written consent will be obtained. All patients will undergo clinical evaluation and relevant investigations. Pregnant women will be instructed to collect their midstream urine sample in a sterile, wide-mouth container, approximately 10 ml, after washing their hands with water and cleaning their genital area using a swab soaked in normal saline. All samples will either be sent to the laboratory within 2 hours or stored in a refrigerator at 4°C and delivered to the laboratory within 18 hours of collection. The patients will be labelled as having UTI (exposed) and not having UTI (non-exposed) based on the operational definitions. The sampling process will continue until both groups have equal number of patients. All the patients will be followed until the parturition. The assessment will be done for the frequency of pre-eclampsia as per operational definitions. The assessment will be made by the consultant who will be kept blind of the exposed/unexposed groups. All patients will be managed as per hospital standard protocols. The results and respective data will be noted down on specially designed proforma attached as Annexure A.

DATA ANALYSIS The data will be analyzed by Statistical package for social sciences (SPSS) version 25 registered for Microsoft Windows. The quantitative variables like age, gestational age, BMI will be expressed as mean ± SD. The quantitative variables like parity, presence of UTI, preeclampsia will be expressed as frequency and percentages. The relative risk (RR) will be calculated for the development of preeclampsia in exposed and non-exposed groups. The data will be stratified for the effect modifiers like age, gestational age ang BMI. The post stratification RR will be recalculated. RR>1 and P value ≤ 0.05 will be considered as significant.

02

Conditions studied

  • Urinary Tract Infection (Diagnosis)
  • Preeclampsia

Keywords

  • Preeclampsia
  • Pregnancy
  • Urinary tract infection
  • Term Birth
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 160 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Pakistan Air Force (PAF) Hospital Islamabad is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women with gestational amenorrhea coming for routine antenatal checkup

Inclusion criteria

  • Patients attending OPD for routine antenatal checkup
  • Patients diagnosed with UTI as per operational definitions
  • Gestational age greater than 20 weeks as per LMP
  • Age between 18 to 35 years

Exclusion criteria

Exclusion Criteria:

  • History of medical conditions such as:
  • Diabetes mellitus
  • Chronic hypertension
  • Chronic liver or kidney diseases
  • Chronic pulmonary conditions
  • History of urological surgical interventions in the past 3 months
  • History of renal transplants
  • Patients on immunosuppressive therapy
  • History of comorbid conditions including:
  • Diabetes mellitus
  • Gestational diabetes mellitus
  • Hypertension
  • Chronic hepatic diseases
  • Chronic liver diseases
  • Chronic pulmonary diseases
  • Ischemic heart diseases
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • UTI exposed

    Patients suffering from UTI as per protocol

    Other: Preeclampsia developed

  • UTI non exposed

    Patients having no clinical and laboratory evidence of UTI

    Other: Preeclampsia developed

Interventions

  • OtherPreeclampsia developed

    Preecalmpsia will be defined as per study protocol

    Also known as: preeclampsia not developed

06

What researchers measure

Primary outcomes

  1. Preeclampsia

    It will be defined as BP \>140/90 mmHg on minimum two occasions after 20 weeks of pregnancy alongside presence of proteinuria (≥300 mg/day or at least 1+ dipstick testing or spot urine protein/creatinine ratio of ≥30 mg/mmol).

    Time frame: 37 weeks of pregnancy

07

Study locations

1 of 1 sites recruiting
  • PAF Hospital, Islamabad
    Islamabad, 45100, Pakistan
    Recruiting
08

References and documents

Publications

  • Johnson CY, Rocheleau CM, Howley MM, Chiu SK, Arnold KE, Ailes EC. Characteristics of Women with Urinary Tract Infection in Pregnancy. J Womens Health (Larchmt). 2021 Nov;30(11):1556-1564. doi: 10.1089/jwh.2020.8946. Epub 2021 Sep 1. PubMed 34491115 ↗
  • Haghdoost S, Pazandeh F, Khabazkhoob M, Bhroozi R. Assocoation Between Sexual and Genital Hygiene Habits with the Urinary Tact Infectin During Pregnancy: A Case-Control Study. International Journal of Women's Health and Reproduction Sciences. 2020;8(2):158-63.
  • Radu VD, Vicoveanu P, Carauleanu A, Adam AM, Melinte-Popescu AS, Adam G, Onofrei P, Socolov D, Vasilache IA, Harabor A, Melinte-Popescu M, Scripcariu IS, Mihalceanu E, Stuparu-Cretu M, Harabor V. Pregnancy Outcomes in Patients with Urosepsis and Uncomplicated Urinary Tract Infections-A Retrospective Study. Medicina (Kaunas). 2023 Dec 7;59(12):2129. doi: 10.3390/medicina59122129. PubMed 38138232 ↗
  • Kaduma J, Seni J, Chuma C, Kirita R, Mujuni F, Mushi MF, van der Meer F, Mshana SE. Urinary Tract Infections and Preeclampsia among Pregnant Women Attending Two Hospitals in Mwanza City, Tanzania: A 1:2 Matched Case-Control Study. Biomed Res Int. 2019 Mar 27;2019:3937812. doi: 10.1155/2019/3937812. eCollection 2019. PubMed 31032344 ↗
  • Stitterich N, Shepherd J, Koroma MM, Theuring S. Risk factors for preeclampsia and eclampsia at a main referral maternity hospital in Freetown, Sierra Leone: a case-control study. BMC Pregnancy Childbirth. 2021 Jun 2;21(1):413. doi: 10.1186/s12884-021-03874-7. PubMed 34078312 ↗
  • Yaqub U, Khattak SN, Khattak MI, Akram U, Gardezi A, Mansoor K. Maternal Urinary Tract Infection and Risk of Preeclampsia: A Cross Sectional Comparative Study. J Soc Obstet Gynaecol Pak. 2022;12(1):1-6.
  • Taghavi Zahedkalaei A, Kazemi M, Zolfaghari P, Rashidan M, Sohrabi MB. Association Between Urinary Tract Infection in the First Trimester and Risk of Preeclampsia: A Case-Control Study. Int J Womens Health. 2020 Jul 10;12:521-526. doi: 10.2147/IJWH.S256943. eCollection 2020. PubMed 32765118 ↗
  • Bajwa FA, Sultana N, Sadaqat A, Riaz A, Sikandar MZ. Factors contributing to preterm birth in patients presenting at tertiary care hospitals in Punjab. J Pak Med Assoc. 2024 Mar;74(3):504-508. doi: 10.47391/JPMA.9474. PubMed 38591287 ↗
  • Getaneh T, Negesse A, Dessie G, Desta M, Tigabu A. Prevalence of Urinary Tract Infection and Its Associated Factors among Pregnant Women in Ethiopia: A Systematic Review and Meta-Analysis. Biomed Res Int. 2021 Dec 1;2021:6551526. doi: 10.1155/2021/6551526. eCollection 2021. PubMed 34901276 ↗
  • Ghouri F, Hollywood A, Ryan K. Urinary tract infections and antibiotic use in pregnancy - qualitative analysis of online forum content. BMC Pregnancy Childbirth. 2019 Aug 13;19(1):289. doi: 10.1186/s12884-019-2451-z. PubMed 31409404 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06962644
Lead sponsor
Pakistan Air Force (PAF) Hospital Islamabad
Responsible party
Wajeeha Fatima (Principal Investigator, Pakistan Air Force (PAF) Hospital Islamabad) — Principal investigator
First posted
May 8, 2025
Start date
Jan 1, 2025
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
May 8, 2025

Study contacts

Wajiha Fatima Resident, MBBS, FCPS (I)
Contact
mwajeeha52@gmail.com
+923338747575

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion